Pages that link to "Item:Q4216701"
From MaRDI portal
The following pages link to Miscellanea. A stopping rule for the continual reassessment method (Q4216701):
Displaying 16 items.
- A note on continual reassessment method (Q274178) (← links)
- Adaptive Bayesian compound designs for dose finding studies (Q434557) (← links)
- Continual reassessment and related dose-finding designs (Q903292) (← links)
- Design efficiency in dose finding studies (Q956828) (← links)
- Operating characteristics of the standard phase I clinical trial design. (Q1285808) (← links)
- Adaptive clinical trial designs for phase I cancer studies (Q2452091) (← links)
- Theoretical study of the continual reassessment method (Q2492919) (← links)
- Dose-Finding Designs for HIV Studies (Q3078854) (← links)
- Continual Reassessment Method for Ordered Groups (Q3079132) (← links)
- Dynamic calibration of pharmacokinetic parameters in dose-finding studies (Q3303574) (← links)
- Consistency of continual reassessment method under model misspecification (Q3837320) (← links)
- Phase I (or Phase II) Dose-Ranging Clinical Trials: Proposal of a Two-Stage Bayesian Design (Q4796210) (← links)
- A new design of the continual reassessment method (Q5082671) (← links)
- Continual reassessment designs with early termination (Q5701130) (← links)
- Retrospective Analysis of Sequential Dose‐Finding Designs (Q5717156) (← links)
- A system for determining maximum tolerated dose in clinical trial (Q5880093) (← links)